
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Troponin T-FS CRISPR Activation Plasmid (h) | sc-402885-ACT | 20 µg | $397.00 | |||
Troponin T-FS CRISPR Activation Plasmid (h2) | sc-402885-ACT-2 | 20 µg | $397.00 |
TNNT3 encodes fast skeletal muscle troponin T (Troponin T-FS), a core component of the troponin complex that anchors tropomyosin on the thin filament and couples Ca²⁺ binding to regulated actin–myosin cross-bridge cycling. By integrating calcium signaling with sarcomere mechanics, Troponin T-FS helps set contraction kinetics, force generation, and fiber-type–specific contractile properties. TNNT3 activity intersects with excitation–contraction coupling and myofibrillar assembly pathways that shape muscle performance and structural integrity. Dysregulation or variation in fast troponin components has been associated with altered contractility and myopathic phenotypes, making TNNT3 a useful node for studying skeletal muscle biology and disease-relevant contractile remodeling.
Troponin T-FS CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous TNNT3 expression without altering the underlying DNA sequence.
Troponin T-FS CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the TNNT3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the TNNT3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Troponin T-FS expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native TNNT3 locus and enabling the study of Troponin T-FS-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Troponin T-FS pathway restoration in tumor cells with silenced or reduced TNNT3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.